Applied Therapeutics Inc
NASDAQ:APLT

Watchlist Manager
Applied Therapeutics Inc Logo
Applied Therapeutics Inc
NASDAQ:APLT
Watchlist
Price: 10.21 USD 6.47% Market Closed
Market Cap: 1.2B USD
Have any thoughts about
Applied Therapeutics Inc?
Write Note

Applied Therapeutics Inc
Accrued Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Applied Therapeutics Inc
Accrued Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accrued Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Applied Therapeutics Inc
NASDAQ:APLT
Accrued Liabilities
$15m
CAGR 3-Years
-9%
CAGR 5-Years
61%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Accrued Liabilities
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Gilead Sciences Inc
NASDAQ:GILD
Accrued Liabilities
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Accrued Liabilities
$14.6B
CAGR 3-Years
16%
CAGR 5-Years
14%
CAGR 10-Years
11%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Accrued Liabilities
$3.2B
CAGR 3-Years
27%
CAGR 5-Years
22%
CAGR 10-Years
28%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Accrued Liabilities
$2.5B
CAGR 3-Years
7%
CAGR 5-Years
25%
CAGR 10-Years
24%
No Stocks Found

Applied Therapeutics Inc
Glance View

Market Cap
1.2B USD
Industry
Biotechnology

Applied Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in New York City, New York and currently employs 34 full-time employees. The company went IPO on 2019-05-09. The Company’s molecular target is aldose reductase (AR), an enzyme that converts glucose to sorbitol under oxidative stress conditions. Its product candidates include AT-007, AT-001, AT-003 and AT-104. The Company’s AT-007 is a central nervous system (CNS) penetrant ARI, which is developed for the treatment of galactosemia. AT-001 is an aldose reductase inhibitor (ARI) with exposure and nerve permeability. AT-001 is developed for the treatment of diabetic cardiomyopathy (DbCM), fatal fibrosis of the heart. Its AT-003 is an ARI designed to cross through the back of the eye when dosed orally. AT-003 is developed for the treatment of diabetic retinopathy (DR). AT-104 is a dual selective PI3K inhibitor in preclinical development for T Cell Acute Lymphoblastic Leukemia (T-ALL).

APLT Intrinsic Value
6.75 USD
Overvaluation 34%
Intrinsic Value
Price

See Also

What is Applied Therapeutics Inc's Accrued Liabilities?
Accrued Liabilities
15m USD

Based on the financial report for Dec 31, 2023, Applied Therapeutics Inc's Accrued Liabilities amounts to 15m USD.

What is Applied Therapeutics Inc's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 5Y
61%

Over the last year, the Accrued Liabilities growth was -1%. The average annual Accrued Liabilities growth rates for Applied Therapeutics Inc have been -9% over the past three years , 61% over the past five years .

Back to Top